Search Within

Shanu Modi

  1. "Larry Norton"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (26)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (53)
  2. Breast Medicine Service (53)
  3. Department of Medicine (53)
  4. Solid Tumor Oncology Division (53)
  5. Survivorship Research (50)
  6. Epidemiology and Biostatistics (38)

More Groups

People
  1. Larry Norton (53)
  2. Clifford Hudis (42)
  3. Chau Dang (28)
  4. Sujata Patil (24)
  5. Maura Dickler (21)
  6. Diana Lake (19)

More People

Years
  1. 2024 (2)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (6)
  6. 2018 (3)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Cancer Research (12)
  3. Clinical Breast Cancer (5)
  4. Annals of Oncology (4)
  5. Clinical Cancer Research (4)
  6. npj Breast Cancer (3)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. American Society of Clinical Oncology (13)
  3. Oxford University Press (6)
  4. Elsevier Inc. (5)
  5. Nature Publishing Group (3)
  6. American Medical Association (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Journal Article

    Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Chang, J. C.; Abbruzzi, A.; Patil, S.; Modi, S.; Seidman, A. D.; Sklarin, N. T.; Norton, L.; Hudis, C.; Fornier, M. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save